Toxicity In Patients With Hepatic Impairment
This drug in combination with capecitabine is contraindicated in patients with AST or ALT > 2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia related death See Contraindications and Warnings and Precautions.
Patient counseling
Package inserts
Additional information
Updated: July 2024
This information provides a SUMMARY of Black Box data from product labeling and does not address all warnings, precautions, or important safety data found in the product insert. It is NOT intended for use in medical decision-making. Patients and healthcare professionals should always consult the most recent product information insert available from the manufacturer, and contact a physician or care provider with any questions. This table may not be complete and may not include all boxed warnings. It is periodically updated with supplemental information from FDA safety alerts, labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.